MedWatch

Bavarian Nordic CEO frustrated with lack of reply on financial support for vaccine candidate

Paul Chaplin, CEO at Bavarian Nordic, is waiting for a reply from the Danish government on financial support for the company's vaccine candidate, according to Danish media.

Photo: Bavarian Nordic / PR

The CEO and president of Bavarian Nordic, Paul Chaplin, tells the Danish media Børsen that he thinks the Danish government is dragging its feet concerning the decision over whether to support the company's vaccine candidate financially.

"Right now, we are frustrated that the negotiations with the (Danish, -ed.) government have been going on for a long time, and if we want to move the program as quickly as possibly, we need to make commitments to contract manufacturers, who will be producing the product and scaling up as preparation for phase III," he tells Børsen, who could not get a comment from the Danish health minister Magnus Heunicke.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs